Keeping pace with the ever-changing life sciences industry, Morrison Foerster stays on top of the trends and political, legal, and economic drivers to support striking the balance between innovative discovery and purposeful business planning to assure our clients continued success. MoFo Life Sciences shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.<a href="https://www.mofo.com/practices/industries/life-sciences/" target="_blank">Learn more about our Life Sciences practice</a>.<a href="https://www.mofo.com/practices/industries/life-sciences/?tab=people" target="_blank">Contact our Life Sciences lawyers</a>.<h2>ABOUT MORRISON FOERSTER</h2>Morrison Foerster is a leading global law firm that transforms complexity into advantage for its clients. Our clients include some of the largest financial institutions, banks, consulting and accounting firms, and Fortune 100, technology, and life sciences companies. Highlighting the firm’s commitment to client service, leadership in market-changing deals and impact litigation, and values-based culture, Morrison Foerster has been repeatedly recognized as one of the top 10 firms on The American Lawyer’s A-List. Year after year, the firm receives significant recognition from Chambers and The Legal 500 across their various guides, including Global, USA, Asia‑Pacific, Europe, UK, Latin America, and FinTech Legal. Our lawyers passionately care about delivering legal excellence while living our values. Morrison Foerster has a long-standing commitment to creating a culture that respects and celebrates differences, while providing an inclusive environment. The firm has achieved Mansfield Certification Plus since 2018 as a result of successfully reaching at least 30 percent women, communities of color, and LGBTQ+ lawyer representation in a notable number of current leadership roles and committees. The firm also has a long history of commitment to the community and society through providing pro bono legal services, including litigating for civil rights and civil liberties, improving public education and fostering the wellbeing of children, advocating for veterans, promoting international human rights, enforcing the right to asylum, and safeguarding the environment.

Social

Search

Subscribe

Life Sciences and Healthcare Group

Life Sciences Podcast

Patent Counseling + Prosecution

FDA Regulatory + Life Sciences Compliance

FDA + Healthcare Regulatory and Compliance 

Life Sciences Transactions + Licensing

Resources

Editors

MoFoLifeSciencesLogo_12202022.png

Wolfgang advises clients on contentious and non-contentious matters involving their most valuable intellectual property assets in the digital, high-tech, life sciences, and pharmaceutical industries.His subjects of focus include research and development collaborations, complex licensing agreements, technology transactions, know-how protection strategies, and employee invention law. He also has substantial experience in litigating patents, trademarks and other intellectual property assets, often in a multijurisdictional context. In addition, Wolfgang and his team frequently clear trademarks and ad campaigns and prosecute trademark applications.Wolfgang is co-editor of our <a href="https://lifesciences.mofo.com/" target="_blank">MoFo Life Sciences Blog</a>.Wolfgang is a partner of Morrison Foerster based in our German office in Berlin.<h4>Representative Experience</h4><h5>Representative Transactional Matters</h5><ul><li>Negotiate multimillion-euro strategic partnership between two AgTech leaders concerning the development and commercialization of pest-resistant transgenic traits.</li><li>Provide commercial and IP advice to startups and established companies in the area of digital health, IoT (5G), and other industry 4.0 or data-driven business models.</li><li>Draft diverse global patent and know-how license agreements in the areas of AgTech and life sciences—including gene licensing and licensing of genome editing technologies (e.g., CRISPR)—medical devices, and draft correlating supply and distribution agreements.</li><li>Structure IP rights in connection with joint ventures and other M&A transactions, including the carve-out of a patent-heavy semiconductor business comprising nine jurisdictions into a German-U.S. joint venture.</li><li>Advise on government-funded, multi-partner R&D projects and/or R&D projects with academic institutions, as well as on employee invention law.</li></ul><h5>Representative Contentious IP Matters</h5><ul><li>Represent leading internet retailer in patent infringement and concurrent invalidity proceedings in the context of a multijurisdictional dispute concerning touch screen technology.</li><li>Represent diverse pharmaceutical and life sciences companies in national and cross-border patent infringement proceedings and other technology-related disputes, including preliminary injunctions as well as pre trial discovery and inspection proceedings, concerning, inter alia, drug coating technologies, toner cartridges, medicinal gases, transgenic plants, and vaccines.</li><li>Conduct trademark, copyright, and false advertising litigation, including, most notably, a high-profile trademark litigation for a German bank, and a nine-country cross-border trademark litigation involving a famous pharmaceutical brand.</li><li>Advise on border seizure measures and trade fair disputes in the areas of household appliances, cosmetics, and sanitary installations, as well as anti-counterfeiting strategies.</li></ul>

Dr. Wolfgang Schönig berät Mandanten zum Schutz des geistigen Eigentums sowohl in streitigen als auch nichtstreitigen Angelegenheiten, mit einem besonderen Fokus auf die IP-rechtliche Beratung von Unternehmen aus den Bereichen Digitalwirtschaft, High-Tech, Life Sciences und Pharmaindustrie.Zu seinen Beratungsschwerpunkten gehören Forschungs- und Entwicklungskooperationen, komplexe Lizenzvertragsgestaltungen, Technologie-Transaktionen, Know-how-Schutz-Strategien und das Arbeitnehmererfinderrecht. Er verfügt zudem über umfangreiche Prozesserfahrung zur Durchsetzung von Patenten, Marken- und anderen IP-Rechten, häufig auch in einem grenzüberschreitenden Kontext. Darüber hinaus bewertet Dr. Wolfgang Schönig zusammen mit seinem Team regelmäßig die Rechtskonformität von Werbekampagnen, prüft die Verfügbarkeit von Marken und entwickelt entsprechende Anmeldestrategien.Dr. Wolfgang Schönig ist Co-Editor des Life Sciences Blogs von Morrison Foerster.Er hat seinen Doktortitel an der Heinrich-Heine-Universität Düsseldorf und seinen LL.M. an der Fordham School of Law in New York erworben, jeweils mit Schwerpunkt im gewerblichen Rechtsschutz. Seinen MBA-Abschluss erhielt er von der European University in Barcelona.Dr. Wolfgang Schönig ist Partner des deutschen Büros von Morrison Foerster in Berlin.<h4>Referenzen</h4><h5>Vertragsgestaltung</h5><ul><li>Verhandlung einer hochvolumigen strategischen Partnerschaft zwischen zwei Technologieführern im Bereich Crop Science betreffend der Entwicklung und Kommerzialisierung von bestimmten Resistenzen.</li></ul><ul><li>Beratung von etablierten Unternehmen und Start-ups zu kommerziellen und IP-rechtlichen Fragestellungen im Bereich Digital Health, IoT (5G) und anderen Industrie 4.0 Sektoren.</li><li>Strukturierung und Verhandlung diverser Patent- und Know-How-Lizenzen in den Bereichen Ag Tech und Life Sciences – einschließlich Fragen zu genome editing wie CRISPR-Medizingeräte, sowie Gestaltung von Softwarelizenzverträgen und Erstellung korrespondierender Liefer- und Vertriebsvereinbarungen.</li><li>Strukturierung von IP-Rechten im Zusammenhang mit Joint Ventures und anderen M&A-Transaktionen, darunter die Koordination eines neun Länder umfassenden IP Carve-Outs im Rahmen eines Halbleiter-JVs.</li><li>Beratung zu staatlich geförderten Multi-Partner F&E-Projekten und/oder F&E-Projekten mit akademischen Einrichtungen sowie zum Arbeitnehmererfindungsrecht.</li></ul><h5>IP-Streitigkeiten</h5><ul><li>Verteidigung einer führenden Internetplattform gegen Ansprüche eines Patenttrolls wegen vermeintlicher Verletzung von Patent bezüglich Touchscreen-Technologie sowie korrespondierende US Streitigkeiten.</li></ul><ul><li>Vertretung von Pharma- und Life Science-Unternehmen in nationalen und grenzüberschreitenden Patentverletzungsverfahren und anderen technologiebezogenen Streitigkeiten, einschließlich einstweiliger Verfügungsverfahren und vorprozessualer Beweissicherungs- und Besichtigungsverfahren, unter anderem in Bezug auf Arzneimittelbeschichtungstechnologien, Tonerkartuschen, medizinische Gase, transgene Pflanzen und Impfstoffe.</li><li>Prozessführung im Markenrecht, Urheberrecht und Wettbewerbsrecht, darunter insbesondere eine hochvolumige Markenstreitigkeit für eine deutsche Bank sowie ein hochkarätiger neun Länder umfassender grenzüberschreitender Markenstreit eine bekannte pharmazeutische Marke betreffend.</li><li>Beratung zu Grenzbeschlagnahmemaßnahmen und Messestreitigkeiten in den Bereichen Haushaltsgeräte, Kosmetik und Sanitär sowie Entwicklung von Strategien zu Anti-Counterfeiting.</li></ul>

schonig_wolfgang_blog_150x150.png

schonig_wolfgang_common_640x280.jpg

schonig_wolfgang_heroretina_2700x1160.jpg

schonig_wolfgang_mobileretina_750x1040.jpg

schonig_wolfgang_social_600x600.jpg

Partner

Wolfgang Schönig is a partner of Morrison Foerster (International) LLP based in our German office in Berlin. His practice specialty is advising on IP aspects relative to transactions in, among others, the life sciences, AgTech and pharmaceuticals industry, as well as legal representation in IP disputes. Wolfgang is specialized in research and development collaborations, complex licensing agreements, technology acquisitions, know-how protection strategies, and employee invention law.

Wolfgang Schönig focuses his practice on IP aspects relative to transactions in the digital, telecoms, high tech, life sciences, and pharmaceuticals industry, as well as legal representation in IP disputes.

Wolfgang Schönig advises clients on IP aspects relating to transactions in, among others, the life sciences, AgTech and pharmaceuticals industry, as well as legal representation in IP disputes. His additional focus areas include research and development collaborations, complex licensing agreements, technology acquisitions, know-how protection strategies, and employee invention law.

Wolfgang Schönig

Anita Choi’s practice focuses on patent prosecution, portfolio management, IP due diligence, and IP litigation support. Her clients range from early-stage start-up enterprises to established domestic and international companies. She is well-versed in building and managing worldwide patent portfolios across many sectors and technologies, including small-molecule pharmaceuticals, medical devices, diagnostics, industrial chemicals and advanced materials, food and agtech.In 2013, Euromoney named Anita an intellectual property rising star at its American Women in Business Law Awards. Anita received her J.D. from the University of Pennsylvania Law School where she graduated magna cum laude and was named to the Order of the Coif. During law school, Anita also completed her M.B.A. at the Wharton School of Business.Anita is co-editor of our <a href="https://lifesciences.mofo.com/">MoFo Life Sciences Blog</a>.Chemistry and Life SciencesAnita gained a solid technical background across disciplines during her time studying at the California Institute of Technology (CalTech), where she received her Bachelor of Science with honors. She spent several years working at Pfizer, developing small molecule compounds for use in oncology therapies. She has performed research at CalTech involving unnatural amino acids, and at MIT involving fluorescent zinc sensors, both for use in developing neuroscience applications.Anita counsels pharmaceutical companies including Bayer, Sanofi/Genzyme, and Jazz Pharmaceuticals on small-molecule patent portfolios. She is also a strategic adviser to many start-up companies in the life sciences and chemicals space, including university spin-offs from UC Berkeley, UC Davis, and MIT.Anita’s patent-portfolio experience in the life sciences industry includes small-molecule pharmaceuticals, cannabinoids, nutraceuticals, polymeric and liposomal formulations, medical devices, diagnostics, and digital health; in the chemicals domain, she concentrates on renewable chemicals, polymers, metal organic frameworks, and energy-storage technologies.Food and AgTechAnita co-leads the firm’s Food and AgTech patent practice. She serves as counsel to large multinational companies in the food and agtech industries as well as to several start-up companies. Her clients in this space include Mars Incorporated, Terviva, Benson Hill, and SoFresh. She has advised businesses in developing IP strategies for soil and crop technologies, sustainable farming, alternative protein sources and extraction technologies, new categories of food and beverage products, and food packaging.Anita’s clients praise her ability to quickly gain a deep understanding of their technology and business, which allows her to think critically, creatively and practically in patent portfolio management. The breadth of technologies that Anita works with also enables her to provide IP advice at the intersection of multiple technical disciplines. For example, Anita’s practice is also well positioned at the convergence of data analytics in the life sciences and agriculture industries.IP Due DiligenceAnita is skillful with investor-side and company-side patent due diligence. She supports many of the firm’s corporate deals, advising on ownership and patent portfolio risks and conducting patentability and freedom-to-operate assessments.IP Litigation SupportAnita also works closely with the IP Litigation Group to formulate strategies for infringement contentions, validity/invalidity contentions, and claim construction positions. She actively supports the patent litigators in pre-litigation diligence matters to evaluate the strength of patents and patent portfolios.Pro BonoAnita has an active pro bono practice and has been awarded the State Bar of California's Wiley W. Manuel Award for Pro Bono Legal Services for many consecutive years. She regularly represents families seeking legal guardianship. She also assists numerous non-profit organizations in developing and securing patent protection for their core technologies.

choi_anita_blog_150x150.png

choi_anita_common_640x280.jpg

choi_anita_heroretina_2700x1160.jpg

choi_anita_mobileretina_750x1040.jpg

choi_anita_social_600x600.jpg

Anita Choi’s practice focuses on patent prosecution, portfolio management, IP due diligence, and IP litigation support. Her clients range from early-stage start-up enterprises to established domestic and international companies. She is well-versed in building and managing worldwide patent portfolios across many sectors and technologies, including small-molecule pharmaceuticals, medical devices, diagnostics, industrial chemicals and advanced materials, food and agtech.

Anita Choi

Stacy Cline Amin leads the FDA + Healthcare Regulatory and Compliance practice within the firm’s Global Life Sciences + Healthcare Group and provides strategic regulatory and business advice to companies in the life sciences, healthcare, and technology industries. Stacy previously served as Chief Counsel of the U.S. Food and Drug Administration (FDA) and Deputy General Counsel of the Department of Health and Human Services (HHS), and held senior positions within the White House Counsel’s Office and health committees in both the House and Senate. With her depth of experience across government agencies, she provides clients with an insider’s perspective on regulatory and compliance issues, enforcement actions, and litigation challenges.As chief counsel of the FDA, Stacy led an office of approximately 170 counselors and litigators and navigated difficult regulatory issues and litigation challenges across the agency’s entire portfolio. During her last year of service, Stacy played a critical role in nearly every aspect of FDA’s COVID-19 pandemic response effort, including record numbers of emergency use authorizations, guidances, and compliance actions. Most notably, she served as a key leader of the team responsible for issuing the first two COVID-19 vaccine authorizations.During her tenure, she served as a trusted strategist and advisor to several FDA Commissioners, including former Commissioner Scott Gottlieb, the FDA Center Directors and Deputy Commissioners, and the HHS Secretary. She worked closely with the leadership of the agency to resolve challenging legal and regulatory issues, including in the areas of human gene therapy and regenerative medicine, in vitro diagnostics, medical device safety and innovation, digital health, animal and plant biotech, food safety, compounding, opioids, and e-cigarettes. She advised on legal issues related to all aspects of the medical product life cycle and worked with Center leadership to resolve novel or challenging issues that arose during product review. She also oversaw the agency’s significant civil and criminal enforcement actions, in coordination with the Department of Justice, and advised on all of the agency’s novel or significant compliance activities.For more than a decade, Stacy’s work has often focused on the intersection of health, life sciences, and technology. At FDA, she advised on the creation and launch of the Digital Health Center of Excellence and oversaw the development of regulations and policy in all areas of digital health, including software as a medical device, artificial intelligence and machine learning, medical device interoperability, and cybersecurity. While serving in Congress, Stacy led multiple bipartisan investigations of digital health, health IT, and cybersecurity issues that resulted in an influential oversight report, a series of six bipartisan hearings, and significant provisions of the 21st Century Cures Act of 2016 and the Cybersecurity Act of 2015.Previously, Stacy served in the White House Counsel’s Office as Senior Associate Counsel to the President, where she advised on matters involving the FDA and Centers for Medicare and Medicaid Services, the Federal Trade Commission, and the Federal Communications Commission.Prior to joining the White House, Stacy served as the Chief Counsel of the Senate Health, Education, Labor and Pensions Committee and as a Counsel for the House Energy & Commerce Committee. She frequently advised on FDA, insurance market, and health IT matters and led significant oversight investigations. These efforts supported a number of legislative accomplishments, including passage of the Drug Quality and Security Act of 2013.Earlier in her career, Ms. Amin served as an associate at two leading Washington, D.C. law firms, where she advised multinational financial services industry clients and startup organizations.She graduated cum laude from Harvard Law School and summa cum laude from the George Washington University in philosophy and clerked for the Hon. John R. Gibson on the U.S. Court of Appeals for the Eighth Circuit.

amin_stacy_blog_150x150.png

amin_stacy_common_640x280.jpg

amin_stacy_heroretina_2700x1160.jpg

amin_stacy_mobileretina_750x1040.jpg

amin_stacy_social_600x600.jpg

Stacy Cline Amin leads the FDA + Healthcare Regulatory and Compliance practice within the firm’s Global Life Sciences + Healthcare Group and provides strategic regulatory and business advice to companies in the life sciences, healthcare, and technology industries. Stacy previously served as Chief Counsel of the U.S. Food and Drug Administration (FDA) and Deputy General Counsel of the Department of Health and Human Services (HHS), and held senior positions within the White House Counsel’s Office and health committees in both the House and Senate. With her depth of experience across government agencies, she provides clients with an insider’s perspective on regulatory and compliance issues, enforcement actions, and litigation challenges.

Stacy Cline Amin

favicon.ico

favicon-16x16.png

favicon-32x32.png

apple-touch-icon.png

MoFo Favicons

MoFo Life Sciences shares timely legal and business insights and in-depth analyses on trends and the complex technologies at the heart of the global pharmaceutical, biotechnology, diagnostics, medical devices, digital health, and AgTech fields.

life-sciences-featured-image.jpg

life-sciences-featured-image

Announcements

Welcome to Mofo Life Sciences

Blog - Terms of Use

Cookies

Blog - Privacy Policy

Blog - Blog Disclaimer

Blog - Attorney Advertising

morrison-foerster-blog-logo.png

Brings together legal insights and in-depth analyses on trends and complex issues shaping the global technology industry.

MoFo Tech Blog

MOFO TECH

Equips our clients with the most up-to-date and relevant information on employment and labor law issues.

Employment Law Commentary

EMPLOYMENT LAW COMMENTARY

Stay on top of emerging issues and stay informed of developments related to the law and business of social media.

Socially Aware

SOCIALLY AWARE

In-depth analysis of developments and trends impacting government contracting.

Government Contracts Insights Blog

GOVERNMENT CONTRACTS INSIGHTS

Provides insights and reports on the most current class actions lawsuits and product liability issues that affect consumer-facing companies.

Class Dismissed Blog

CLASS DISMISSED

MoFo Life Sciences

  Linkedin

MoFo LinkedIN

Twitter

MoFo Twitter

Life Sciences Blog - RSS

Stay Connected

Never miss a post from MoFo Life Sciences. Enter your email below to stay up-to-date.

Because No One is Immune to the Law

Morrison Foerster - Footer

Blogs -  Home Button

Home

Blog - Topics

AI + Robotics

Agtech

Antitrust

Asia

Bioinformatics

Biotech

Blockchain

Cell + Gene Therapy

CFIUS

Corporate + Venture Capital

COVID-19

Data Analytics

Digital Health

Employment

European Union

Financing

Global

Healthcare

Intellectual Property

Licensing + Commercial

Litigation

Medical Devices + Diagnostics

Pharma

Privacy + Data Security

Product Liability + Class Action

Rare Disease

Regulatory

Startup

United Kingdom

United States

Topics

Blog - Editors

Blog - About

About

Blog - Subscribe

More

Patent Term Adjustment Takes a Hit in Cellect Decision

A Glimmer of Hope for Simplified Patenting of Medical Diagnostics in the United States

Biden Executive Order Has Potential to Discourage U.S. Company Participation in Federal Research

Medicare Drug Price Negotiation Program Final Guidance

5 Questions About Generative AI in Healthcare

LinkedIN

This article is Part B of the fifth alert in our series of alerts focussed on the alternative protein industry. While Part A provided an overview of financing options in the industry, this Part B considers a variety of key financing options in more detail, including important considerations for nascent companies.Read the <a href="https://www.mofo.com/resources/insights/221207-financing-options-in-the-alternative-protein-industry" target="_self">full client alert</a>.

arlington_simon_blog_150x150.png

arlington_simon_common_640x280.jpg

arlington_simon_heroretina_2700x1160.jpg

arlington_simon_mobileretina_750x1040.jpg

arlington_simon_social_600x600.jpg

Simon Arlington is a partner based in the Corporate Group focusing on M&A and private equity. 
Simon represents clients across all aspects of M&A and private equity, including raising capital, acquisit

Simon Arlington is a partner based in the Corporate Group focusing on M&A and private equity.
 Simon represents clients across all aspects of M&A and private equity, including raising capital, acquisit

Simon Arlington

burge_john_blog_150x150.png

burge_john_common_640x280.jpg

burge_john_heroretina_2700x1160.jpg

burge_john_mobileretina_750x1040.jpg

burge_john_social_600x600.jpg

John Burge is a partner based in the London office.
Mr. Burge has extensive experience as a finance lawyer advising both lenders and borrowers on their investment grade, leverage and restructuring tra

John Burge

van-der-griendt_laura_blog_150x150.png

van-der-griendt_laura_common_640x280.jpg

van-der-griendt_laura_heroretina_2700x1160.jpg

van-der-griendt_laura_mobileretina_750x1040.jpg

van-der-griendt_laura_social_600x600.jpg

Associate

Laura advises both lender and borrower side on a range of local and cross-border leveraged and acquisition finance transactions, and also represents private equity firms and corporate issuers in relation to high yield and investment grade debt transactions.

Laura Van Der Griendt

221205-pvp-blog-image.jpg

Financing Options in the Alternative Protein Industry

221205-pvp-blog-image

This article is Part B of the fifth alert in our series of alerts focussed on the alternative protein industry. While Part A provided an overview of financing options in the industry, this Part B considers a variety of key financing options in more detail, including important considerations for nascent companies.

Financing Options in the Alternative Protein Industry

Having a clear picture of financing options is key for early-stage companies and will be relevant to players in the alternative protein industry generally, given the significant amounts of investment that the industry has seen in recent years (a record US $5bn was invested in 2021) and the rapid growth we are seeing in companies in this sector.Read the <a href="https://www.mofo.com/resources/insights/221020-financing-options-for-an-early-stage-company?utm_source=publication&utm_medium=email" target="_self">full client alert</a>.

Yara International ASA

Initial purchasers

Investors

International Design Group S.p.A. (a Carlyle and Investindustrial portfolio company)

Sisal Group S.p.A. (a CVC portfolio company)

Fire (BC) S.p.A. (a Bain Capital portfolio company)

Ithaca Energy Limited

Neptune Energy Bondco plc

Schumann S.p.A. (a CVC portfolio company)

Aker BP ASA

DEA Finance SA (an L1 Energy portfolio company)

dunlap_matthew_blog_150x150.png

dunlap_matthew_common_640x280.jpg

dunlap_matthew_heroretina_2700x1160.jpg

dunlap_matthew_mobileretina_750x1040.jpg

dunlap_matthew_social_600x600.jpg

Matthew  Dunlap is a partner based in  the London office. His practice focuses on complex cross-border transactions,  including high yield and crossover debt offerings, acquisition financings and  lia

Matthew Dunlap

Financing Options for an Early Stage Company in the Alternative Protein Industry

Having a clear picture of financing options is key for early-stage companies and will be relevant to players in the alternative protein industry generally, given the significant amounts of investment that the industry has seen in recent years (a record US $5bn was invested in 2021) and the rapid growth we are seeing in companies in this sector.

Financing Options for an Early Stage Company in the Alternative Protein Industry

Investment in the alternative protein industry is surging, and companies are increasingly capitalising on opportunities to partner with each other in this area. Where the partners bring roughly an equal share to the table, these partnerships may be referred to as JVs. JVs are commercial arrangements agreed between those partners for the purpose of achieving a specific objective. They may be contractual JVs between existing entities without forming a new company, or corporate joint ventures, where a new limited liability company or partnership is formed between the partners. JVs are an effective way for companies to pool technology, expertise and resources in order to generate profit and capture market share.Read the <a href="https://www.mofo.com/resources/insights/220223-quick-guide-jvs-alternative-protein-industry" target="_self">full client alert</a>.

Autodesk

HM Revenue and Customs

Home Office, Department for Communities and Local Government, Department of Health

Intel

ITworx

lastminute.com

NYSE-listed health tech company

One of UK's largest public EV charging networks

Phoenix Group

Telenor

UK Border Agency

maughan_alistair_blog_150x150.png

maughan_alistair_common_640x280.jpg

maughan_alistair_heroretina_2700x1160.jpg

maughan_alistair_mobileretina_750x1040.jpg

maughan_alistair_social_600x600.jpg

Alistair Maughan co-leads Morrison & Foerster's European Technology & Commercial Practice.

Alistair Maughan

Alistair advises on the deployment of new technology platforms involving, for example, the internet of things, AI and machine-learning, and blockchain and distributed ledger technology.

Quick Guide to JVs in the Alternative Protein Industry

Topic Archives: Financing

Financing Options in the Alternative Protein Industry

By: Simon Arlington, John Burge and Laura Van Der Griendt

Financing Options for an Early Stage Company in the Alternative Protein Industry

By: Simon Arlington and Matthew Dunlap

Quick Guide to JVs in the Alternative Protein Industry

By: Alistair Maughan and Simon Arlington

An Easier Road to a Hong Kong Listing for Biotech Companies

By: Vivian Yiu, Janet Xiao and Jie Zhou

Startup diligence is more than ‘basic IP diligence’